Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Abstract Background Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targe...

Full description

Bibliographic Details

Published in:	Neuro-oncology (Charlottesville, Va.) Vol. 25; no. 11; pp. 2058 - 2071
Main Authors:	Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 02.11.2023
Subjects:	Glioblastoma - pathology Humans Immunotherapy, Adoptive - methods Killer Cells, Natural Neoplasm Recurrence, Local - drug therapy Receptors, Chimeric Antigen Recurrence human clinical trial NK cells glioblastoma CAR in HER2 phase I first adoptive immunotherapy
ISSN:	1522-8517, 1523-5866, 1523-5866
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!